DK1759709T3 - Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 - Google Patents

Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4

Info

Publication number
DK1759709T3
DK1759709T3 DK06013916.9T DK06013916T DK1759709T3 DK 1759709 T3 DK1759709 T3 DK 1759709T3 DK 06013916 T DK06013916 T DK 06013916T DK 1759709 T3 DK1759709 T3 DK 1759709T3
Authority
DK
Denmark
Prior art keywords
humanized antibodies
adhesion molecule
leukocyte adhesion
molecule vla
vla
Prior art date
Application number
DK06013916.9T
Other languages
English (en)
Inventor
Mary M Bendig
Olivier J Leger
Jose Saldanha
Tarran S Jones
Theodore A Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of DK1759709T3 publication Critical patent/DK1759709T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06013916.9T 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 DK1759709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
EP95908741A EP0804237B8 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (1)

Publication Number Publication Date
DK1759709T3 true DK1759709T3 (da) 2013-06-10

Family

ID=22684288

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95908741T DK0804237T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4
DK06013916.9T DK1759709T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK95908741T DK0804237T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4

Country Status (21)

Country Link
EP (2) EP0804237B8 (da)
JP (5) JP4115517B2 (da)
KR (1) KR100367948B1 (da)
CN (1) CN1211123C (da)
AT (1) ATE333895T1 (da)
AU (1) AU703152B2 (da)
CA (1) CA2182013C (da)
DE (2) DE69535133T2 (da)
DK (2) DK0804237T3 (da)
ES (2) ES2270425T3 (da)
FI (1) FI117509B (da)
FR (1) FR06C0024I2 (da)
HU (1) HU220799B1 (da)
LU (1) LU91271I2 (da)
MX (1) MX9602971A (da)
NL (1) NL300238I2 (da)
NO (3) NO319867B1 (da)
NZ (1) NZ279730A (da)
PL (1) PL181827B1 (da)
PT (1) PT804237E (da)
WO (1) WO1995019790A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ATE418999T1 (de) * 1998-09-14 2009-01-15 Univ Texas Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
SK287328B6 (sk) 1999-04-22 2010-07-07 Biogen Idec Ma Inc. Použitie kompozície obsahujúcej homológ protilátky, ktorý je antagonistom interakcie medzi integrínom nesúcim podjednotku alfa4 a ligandom pre integrín nesúci podjednotku alfa4
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
BR0011250A (pt) 1999-06-01 2002-03-05 Biogen Inc Anticorpo monoclonal de bloqueio a vla-1 e seu uso para o tratamento de distúrbios inflamatórios
DK1242118T3 (da) * 1999-12-16 2010-01-11 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonister
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2443903C (en) 2001-04-13 2018-03-20 Biogen, Inc. Antibodies to vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ATE512163T1 (de) * 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
AU2003226065B2 (en) * 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
AU2003298187B2 (en) * 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP2615087A3 (en) 2003-12-22 2013-08-07 Ajinomoto Co., Inc. Phenylalanine derivatives
CA2587597A1 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
AU2007267579B2 (en) 2006-05-25 2013-05-30 Biogen Ma Inc. Methods of treating stroke
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
LT2170390T (lt) * 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
CN101889036B (zh) 2007-12-13 2013-01-02 株式会社德山 光致变色固化性组合物
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5498566B2 (ja) 2009-03-20 2014-05-21 アムジェン インコーポレイテッド アルファ−４−ベータ−７ヘテロ二量体特異的アンタゴニスト抗体
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
LT2558499T (lt) 2010-04-16 2017-07-25 Biogen Ma Inc. Antikūnai prieš vla-4
CN108969469A (zh) 2011-05-02 2018-12-11 米伦纽姆医药公司 抗α4β7抗体的制剂
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126A1 (en) * 2017-02-17 2019-12-25 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US20200199525A1 (en) 2017-06-08 2020-06-25 Polpharma Biologics S.A. Improved Methods of Cell Culture
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
AU674302B2 (en) * 1992-02-12 1996-12-19 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
NO319867B1 (no) 2005-09-26
PL181827B1 (pl) 2001-09-28
CA2182013C (en) 2007-07-17
NO963097L (no) 1996-09-24
EP0804237A4 (en) 2003-04-16
AU703152B2 (en) 1999-03-18
CN1211123C (zh) 2005-07-20
NL300238I1 (da) 2006-10-02
ATE333895T1 (de) 2006-08-15
DK0804237T3 (da) 2006-10-16
NO963097D0 (no) 1996-07-24
JP2006045237A (ja) 2006-02-16
JP2013165718A (ja) 2013-08-29
EP0804237B8 (en) 2006-11-08
EP0804237B1 (en) 2006-07-26
JP2013173738A (ja) 2013-09-05
CA2182013A1 (en) 1995-07-27
LU91271I2 (fr) 2006-10-02
PT804237E (pt) 2006-10-31
PL315634A1 (en) 1996-11-25
ES2270425T3 (es) 2007-04-01
MX9602971A (es) 1998-01-31
NL300238I2 (nl) 2007-05-01
NZ279730A (en) 1998-04-27
NO2006008I2 (no) 2009-06-15
EP0804237A1 (en) 1997-11-05
KR970700513A (ko) 1997-02-12
FR06C0024I1 (da) 2006-10-13
AU1696095A (en) 1995-08-08
DE69535133T2 (de) 2008-08-21
HUT75129A (en) 1997-04-28
EP1759709A1 (en) 2007-03-07
DE69535133D1 (de) 2006-09-07
FI962958A0 (fi) 1996-07-24
HU9602019D0 (en) 1996-09-30
NO2006008I1 (no) 2006-08-07
WO1995019790A1 (en) 1995-07-27
EP1759709B1 (en) 2013-02-27
JPH09508272A (ja) 1997-08-26
HU220799B1 (hu) 2002-05-28
KR100367948B1 (ko) 2003-07-12
NO2017040I2 (no) 2018-08-28
NO2017040I1 (no) 2017-08-01
JP2009235078A (ja) 2009-10-15
FR06C0024I2 (fr) 2009-01-02
ES2424292T3 (es) 2013-09-30
CN1140413A (zh) 1997-01-15
FI962958A (fi) 1996-09-24
FI117509B (fi) 2006-11-15
JP5487382B2 (ja) 2014-05-07
JP4115517B2 (ja) 2008-07-09
DE122006000043I1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
DK1759709T3 (da) Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
NO961151L (no) Antistoffer mot CD40
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
RS80704A (en) ANTI- av?6.ANTIBODIES
ATE218387T1 (de) Antikörperreinigung
ATE155818T1 (de) Nicht glycosylierter anti-cd3-igg-antikörper
ATE531812T1 (de) Humanisierung von nager-antikörpern
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
DK1414861T3 (da) Humaniserede antistoffer mod ICAM-1, fremstilling og anvendelse heraf
IL141158A0 (en) A humanized immunoglobulin which binds to human von willebrand factor
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
DE69601154T2 (de) Zubereitungen für die Behandlung von Hepatitis C